BUZZ-Gilead Sciences falls after quarterly sales miss estimates ** Shares of drugmaker Gilead Sciences GILD.O fall 3.4% to $102.59 in extended trading
** Company reports Q1 sales of $6.67 bln, below analysts' estimates of $6.81 bln, according to data compiled by LSEG
** Sales of company's cancer drug, Trodelvy, fell 5% to $293 mln
** Sales of company's COVID-19 antiviral, Veklury, fell 45% to $302 mln
** However, company reports Q1 adj. profit of $1.81/shr, above analysts' estimates of $1.79/shr
** As of last close, stock up 14.8% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.